Alemtuzumab: Powerful Treatment, Benefits, and Important Risks

What Is Alemtuzumab?

Alemtuzumab is a monoclonal antibody drug used to treat multiple sclerosis (a disease where the immune system attacks the protective covering called myelin)and B-cell chronic lymphocytic leukemia. It functions by identifying and eliminating particular cells, especially those that express the CD52 protein, which is present on some cancerous and white blood cells.

How Does Alemtuzumab Work?

Mechanism of Action: Target Cells and Immune Modulation

Alemtuzumab destroys certain immune system-produced cells known as T and B cells. They typically target bacteria and viruses that enter your body. These cells, however, attack the myelin sheath that envelops the nerves in your brain and spinal cord when you have multiple sclerosis (MS). Alemtuzumab prevents these cells from entering your brain and spinal cord, preventing nerve damage.

Alemtuzumab causes complement-mediated lysis and antibody-dependent cellular cytolysis after attaching to the cell surface of T and B cells. The depletion and repopulation of lymphocytes, as well as changes in the quantity, composition, and characteristics of certain lymphocyte subsets after treatment, as well as an increase in the representation of regulatory T cell subsets and memory T- and B-lymphocytes, imply that Alemtuzumab may also have immunomodulatory effects. Alemtuzumab's decrease in the number of circulating B and T cells and their subsequent repopulation may reduce the chance of relapse, which would ultimately slow the course of the disease.

What Are the Uses and Indications of Alemtuzumab?

FDA-approved Uses of Alemtuzumab:

The United States Food and Drug Administration (FDA) has approved Alemtuzumab for the following conditions:

1. Multiple sclerosis (MS) that recurs, particularly for adults who have not responded well to two or more previous treatments. It may slow the progression of disability and help lower the frequency of relapses.

2. In chronic lymphocytic leukemia (blood cancer), Alemtuzumab aids in the reduction of malignant B-cells by targeting the CD52 protein on them.

What Is the Dose and How Is Alemtuzumab Administered?

Alemtuzumab injection is administered intravenously (into a vein) by a physician or nurse in a hospital as a solution (liquid) over a minimum of two hours. To allow the body to adjust to the medication, Alemtuzumab is usually given in gradually increasing dosages for three to seven days at first. Once the body has adjusted to the necessary dosage, Alemtuzumab is usually given three times a week on different days for a maximum of 12 weeks.

Recommended Dosage:

1. For Multiple Sclerosis:

• Initial course: 12 mg (milligrams) daily for five days in a row.

• 12 months later, the second course: 12 mg daily for three days in a row.

2. Regarding B-cell Chronic Lymphocytic Leukemia:

• Standard initial dosage: 3 mg intravenously.

• Raised gradually for a maximum of 12 weeks to a maintenance dosage of 30 mg, three times per week.

• To reduce adverse effects, dose escalation is done carefully.

Missed Dose

It is critical to get in touch with your healthcare provider right away if a dose is missed. Dosing schedules may need to be adjusted, so do not try to make up for the missed dose without first consulting a doctor.

Over Dose

Alemtuzumab overdose can cause immune suppression and serious infections. If an overdose is suspected, immediate medical attention is required. Treatment usually includes supportive care and close monitoring.

What Are the Side Effects and Risks of Alemtuzumab?

Common Side Effects after Infusion of Alemtuzumab:

• Infections of the sinuses (the areas surrounding your nose), throat, urinary tract, and chest.

• Headaches.

• A skin rash called hives.

• Fatigue.

• Fever.

• Itching.

• Getting a red rash on the neck and face.

• Experiencing fatigue.

Serious and Rare Adverse Effects of Alemtuzumab:

• Thyroid Issue - Developing a thyroid issue is one of the more severe side effects; up to four out of ten people experience this. Although it can be treated, lifelong medication is required. Alemtuzumab can still be taken.

• ITP (Immune Thrombocytopenia) - It is a blood disorder that affects one to three people out of every hundred. Although it can be quite dangerous, if detected early enough by a blood test, it is treatable. Check for any bruising or excessive bleeding, are these are the usual symptoms.

• Pregnancy - Planning for a family while taking Alemtuzumab? This is a really important topic to be discussed with your doctor. You should not take this medication if you are pregnant, trying to conceive, or not using contraception because it can harm unborn children. Pregnancy prevention is crucial for the duration of each treatment and for four months afterwards.

What Are the Precautions and Contraindications of Alemtuzumab?

• If you have any allergies to Alemtuzumab injection or any other medication, let your doctor and pharmacist know.

• If you are on any medication, let the doctor know before taking Alemtuzumab.

• If you currently have any medical conditions or have ever had any. Please inform your doctor during the consultation.

• Inform the physician if the patient is pregnant or plans to get pregnant. To avoid getting pregnant during treatment and for four months following your last dose, you must use birth control and take a pregnancy test before beginning treatment. Contact your physician right away if you become pregnant while receiving an Alemtuzumab injection. Alemtuzumab could be harmful to the fetus.

• If you are having surgery, let the doctor know before taking Alemtuzumab.

How Does Alemtuzumab Affect Pregnancy?

Alemtuzumab may be harmful to fetuses. Therefore, you must avoid getting pregnant for four months following your last infusion or while taking this medication. This medication has a "washout period" of four months. It takes that long for your body to produce enough of it for pregnancy to be safe. Since you can safely become pregnant in the years that follow your last infusion, Alemtuzumab may be a good option if you want children.

Conclusion

Alemtuzumab is a disease-modifying medication (DMT) used to treat relapsing multiple sclerosis. B-cell chronic lymphocytic leukemia (B-CLL), a slowly developing cancer in which the body produces an excessive amount of a specific type of white blood cell, is treated with Alemtuzumab injections. Alemtuzumab belongs to the class of medications known as monoclonal antibodies. It kills cancer cells by invigorating the immune system. Rashes, headaches, nausea, insomnia, upper respiratory tract infections, exhaustion, fever, flushing, itching, and a drop in white blood cell count are typical adverse effects. To ensure that this medication is functioning as intended, your doctor must regularly check in with you and closely monitor your progress. Blood and urine tests may be necessary during treatment and for 48 months after your last dosage to look for.

Key Takeaways:

Active secondary progressive disease and relapsing-remitting disease are two types of relapsing multiple sclerosis (MS) that are treated with Alemtuzumab. This medication may lessen the frequency of MS relapses and slow some of the disease's incapacitating effects, but it would not cure MS. It should only be used in cases where two or more MS treatment medications have failed. To know more about these medications, consult our specialists at iCliniq.